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Ferracyclic carbonyl complexes as anti-inflammatory agents 
Mark A. Wright,a Tyler Wooldridge,b Maria A. O’Connell*b and Joseph A. Wright*a
Reaction of Fe(CO)4Br2 with 2-aminopyridine and 2-
aminonapthalene yields ferracyclic iron(II) complexes bearing two 
CO ligands. Irradiation with visible light releases these two CO 
molecules. Substitution of halide in parent complexes by 
thioglucose provides significantly and raises the quantum yield for 
CO release is raised by around five times. The complexes show 
anti- inflammatory activity in a TNF assay in the dark. 
Carbon monoxide (CO) acts a bioregulator and exerts a wide 
range of protective effects in tissues at physiological 
concentrations. Over the past decade, the therapeutic 
potential of CO in various conditions including 
neurodegenerative and cardiovascular diseases has been 
recognized1,2 and is likely to be partly due to their anti-
inflammatory properties. Preclinical trials have shown that 
exogenous CO can act as a therapeutic agent,3 bringing about 
a range of beneficial effects including inflammatory 
suppression4,5 and vasodilation.6,7 A critical challenge to 
overcome is the inherent toxicity of CO and to optimize its 
therapeutic delivery in a safe and tightly-controlled manner. 
One leading strategy is the application of metal carbonyl 
complexes bearing labile CO ligands. These carbon monoxide 
releasing molecules (CORMs) allow for molecular storage of 
one or more CO equivalents, which will only liberate the gas 
when subjected to a particular trigger mechanism. 
 A particularly attractive approach to controlled release of 
CO is to use an external stimulus to provide both special and 
temporal control. The leading method to achieve this at 
present is to use (visible) light to degrade dark-stable 
molecules: so-called photoCORMS.8–13 Whilst Mn(I) complexes 
have received particular interest in the development of visible-
light photoCORMs,14–16 the potential of iron-based systems, 
has received more limited attention.17–20 Appropriately 
chelating  
 
Scheme 1. Synthesis of complexes. 
this transition metal offers the prospect of creating benign 
photoCORM systems complementary to the more extensive 
family of manganese-based systems. 
 We have previously reported a structural mimic of the 
photosensitive [Fe]-hydrogenase active site (1, Scheme 1),21,22 
featuring a low-spin Fe(II) centre and bearing two discrete CO 
ligands. We reasoned that the combination of a pyridyl 
chromophore with the CO-rich metal centre could provide a 
platform on which to build novel iron-based photoCORMs 
activated by visible light. Gratifyingly, the photoactivity of 1 
was readily confirmed by monitoring the infrared (IR) region, 
with rapid loss of the starting materials cis-CO signature over a 
two hour time frame on irradiation with visible light. 
 Extending the aromatic system of 1 by introduction of a 
naphthyl ring was facile, and proceeded to yield the light-
sensitive 2 by the same route (Fig. 1, top). 
 A central requirement for any practical photoCORM is that 
it is deliverable in aqueous media.23 Introduction of a 
saccharide group offers the possibility to both confer water 
solubility and to influence cellular targeting. Ruthenium- and 
molybdenum-based photoCORMs bearing peptide or 
protected sugar functions have been described but these are 
only active in the ultraviolet region (UV).24,25 By exploiting 
dinuclear cores related to 1 and bearing thioglucose ligands, 
we have now developed photoCORMs which release CO in the 
visible region and are soluble in water. 
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Figure 1. Ball-and-stick representations of the structure of 1·MeCN (top) and 
4·3(MeOH)·1.5(H2O) (bottom); solvent molecules and hydrogen atoms bound to 
carbon (bottom) are omitted for clarity. For ORTEP representations see ESI.‡,§ 
 Replacement of the halide in 1 has been established using 
simple aromatic thiols,21,22 and was successful in generating 3 
and 4 in MeOH solution. The latter was readily crystallised as 
the methanol/water solvate (Fig. 1), confirming the presence 
of the desired Fe−S linkage along with dimer formation.21 
Whilst the parent complexes are insoluble in pure water, 3 can 
be dissolved in water at concentrations of at least 35 mM. The 
ultraviolet spectra of 1−4 in DMSO reveal that whilst the most 
significant bands are in the ultraviolet region, the compounds 
exhibit absorption into the visible (Fig. 2, λ > 400 nm). On a 
per-metal basis, the monomeric and dimeric systems show 
similar UV-visible behaviours in the ultraviolet and visible 
ranges. 
 Quantitative assessment of photoCORM potential was 
carried out using the myoglobin assay26 with irradiation from a 
cold visible light source at two power levels (0.216 W and 
0.840 W). Carbon monoxide release was monitored in buffer 
solution, with the metal complexes added dissolved in water  
 
Figure 2. UV-vis spectra for photoCORMs in DMSO. 
(3), water−DMSO 49 : 1 (4) or DMSO (1 and 2). The assays 
were performed at concentrations of 10 µM, 20 µM and 30 
µM. The apparent rates of CO photorelease (kCO) and quantum 
yields (Φ) are given in Table 1. Both complexes 3 and 4 release 
two molecules of CO per mole (i.e. one per metal centre) 
during the assay. With the proviso that varying amounts of 
DMSO were required to solubilise the complexes, it is possible 
to compare the release behaviours of the systems: the rate of 
CO release in the dimeric complexes is significantly raised 
compared with the monomeric parents (Fig. 3). 
 The assay data is also indicative of a change of mechanism: 
whilst release from the monomeric systems may be fitted 
using a single exponential function, a two-term exponential is 
required to model the behaviour of the dimeric systems. A 
two-step mechanism involving distinct loss mechanisms for the 
first and second CO equivalents from 3 and 4, possibly driven 
by strong hydrogen bonding, may explain this behaviour. To 
date we have been unable to identify signals corresponding to 
such an intermediate, and are pursuing this both synthetically 
and by ultrafast pulse-probe methods. 
 Typically, the term ‘photoCORM’ is applied to any molecule 
which releases CO on exposure to (ultraviolet or visible) light,9 
and so a positive response in the myoglobin assay is normally 
regarded as sufficient to describe materials as photoCORMs. 
This is an effective screening method given the increasing 
number of putative photoCORMs reported in recent years, but 
Table 1. Apparent rate of CO release (kCO) and associated quantum yields (Φ) for 1−4 at 
two different irradiation powers. 
Complex [b] Ave. rate (kCO)[a]/(10−3 
min−1) 
Quantum yield (Φ)[b]/10−5 
 0.216 W 0.840 W 0.216 W 0.840 W 
1[c] 7.7(10) 15.9(6) 15.4 1.39 
2[c] 7.9(6) 23(4) 15.8 1.49 
3[d] 17.1(15) 107(6) 17.0 9.31 
4[e] 17.5(4) 111(4) 17.4 9.67 
a] As determined as the average of myglobin assays at 10 µM, 20 µM and 30 µM 
solutions. [b] Using a broadband visible light source. [c] Dissolved in DMSO. [d] 
Dissolved in water. [e] Dissolved in water−DMSO 49 : 1. 
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Figure 3. CO release from 2 and 4 as assessed by a myoglobin assay at a light 
power of 0.840 W, [complex]0 = 30 µM. Points: experimental data; lines: 
exponential fits. Inset shows full time course for release from 2. 
can only be a precursor to more detailed in vitro testing for 
activity in a biological context.  
 There are several different approaches to in vitro testing of 
putative photoCORMs. Cell viability screening,27–31 is vital to 
establish that photoCORMs are not themselves harmful, but 
does not directly provide information on active therapeutic 
potential. Studies on anti-cancer,32–35 anti-microbial36,37 and 
ion channel activity38 have been reported in recent years, but 
cover only a small number of the total reports of putative 
photoCORMs. Anti-inflammatory activity is well-established for 
CO and is therefore an area which is a key target for 
(photo)CORM application. However, to date we are unaware 
of any photoCORM systems shown to exhibit anti-
inflammatory activity in vitro.39 
 Anti-inflammatory activity for complexes 1–4 was assessed 
by studying the inhibitory effects on lipopolysaccharide-
induced tumour necrosis factor-alpha (TNF) secretion in 
human THP_1 monocytes40 We have previously validated this 
in vitro model of inflammation.40,41 We investigated the anti-
inflammatory activity of complexes 1–4, both in the light and 
in the dark (Fig. 4); control experiments established that the 
compounds did not affect cell viability at the concentrations 
used (IC50 >1 mM for all compounds, data not shown). 
Surprisingly, in the light there was no evidence for any activity 
for compounds 1 or 3, with limited efficacy for complex 4. On 
irradiation, complexes 2 and 4 showed statistically-significant 
activity, though in the latter case the degree of suppression 
was small (13.9%). In contrast, assay experiments carried out 
in the dark revealed 51% suppression of inflammatory 
response for compound 1 and 72 % suppression for compound 
2. The more elaborate structures 3 and 4 again were 
disappointingly ineffective, with no significant suppression of 
TNF release. 
 The contrast between myoglobin and TNF assay results 
here is striking. The myoglobin data establish that complexes 
1–4 release CO in response to irradiation (and not by 
hydrolysis), but it is clear from the TNF data that this is not  
 
Figure 4. Anti-inflammatory effects of photoCORMs. THP-1 monocytes were 
pre-treated with photoCORMs (50 μM) for 30 min prior to addition of 
lipopolysaccharide (for 3 h) to stimulate TNF secretion. TNF in cell supernatants 
was measured by ELISA (BD Biosciences). Values are relative to control LPS-
activated DMSO-treated cells (means, + SD, three biological replicates). 
under stress is not sufficient for activity. One may speculate 
responsible for suppressing the inflammatory response; as 
noted in Table 1, release of CO in the myoglobin assay is 
dependent on illumination of the substrates. Thus releasing CO 
close to cells that this points to a requirement for cellular 
uptake as part of the overall mode of action of these 
compounds. The structural variations present in the complexes 
may offer some insight. Complexes 3 and 4 are dimeric and 
may therefore be too large to enter viable cells, despite their 
favourable solubility characteristics. Efforts to elucidate the 
background to this contrasting behaviour are ongoing. 
 In summary, a family of photoCORM molecules have been 
developed featuring a ferracyclic core. All release CO in 
response to irradiation with visible light as detected by a 
myoglobin assay. However, anti-inflammatory activity is only 
seen in the dark, suggesting an alternative mode of action is in 
play. The results here emphasise the need to look beyond the 
myoglobin assay to in vitro testing in the development of 
practical leads for therapeutic photoCORM systems. 
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‡ Crystal data for 2·MeCN: Empirical formula C16H13BrFeN4O3; 
Formula weight 445.06; Crystal size/mm3 0.09 × 0.06 × 0.01; 
Crystal system triclinic; Space group P–1; a/Å 8.0450(6); b/Å 
8.9535(6); c/Å 12.1950(9); α/° 96.322(6); β/° 91.386(5); γ/° 
92.148(5); V/Å3 872.11(11); Z 2; MoKα (λ = 0.71075); Reflections 
collected 15 491; Independent reflections 3981; Rint = 0.0492;  
Data/restraints/parameters 3981/1/232; R1 [I >= 2σ(I)] 0396; 
wR2 [all data] 0.1148. 
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§ Crystal data for 4·3(MeOH)·1.5(H2O). Empirical formula 
C39H51Fe2N4O20.5S2; Formula weight 1079.66; Crystal size/mm3 
0.38 × 0.35 × 0.25; Crystal system monoclinic; Space group C2; 
a/Å 23.8608(7); b/Å 13.3771(5); c/Å 15.4092(5); β/° 101.705(3); 
V/Å3 4816.2(3); Z 4; MoKα (λ = 0.71073); Reflections collected 
35 958; Independent reflections 10 847; Rint = 0.0634, ; 
Data/restraints/parameters 10847/23/644; R1 [I >= 2σ(I)] 
0.0619, wR2 [all data] 0.1696; Flack parameter –0.02(3). 
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